Abstract
Effects of the homologous anti-Yoshida-sarcoma-subline-cell-serum upon antigen-cells was investigated in in vivo.
Intraperitoneal injection of the antiserum, resulted in no elongation of survival time in tumor-bearing rats in a maximum dose. Rats which received 4 to 6 ml of the antiserum on the 1st day of tumor transplantation survived over a relatively longer period than any others. Further, the tumor cells after treatment showed a marked fall in frequency of occurrence of mitosis and in cytoplasmic basophilia with a subsequent breakage of the cytoplasm.
Use of the neotetrazolium method yielded information that the tumor cells treated with antiserum were unable to utilize the exogeneous succinate, though there occurred an increased ability to utilize exogeneous glucose by tumor cells. Such a neotetrazolium reduction occurred 6 to 12 hours after the injection of antiserum. The gradual return to normal level was attained 3 to 4 days after injection in the case when booster injection was not given.
